Market reporting

UK financial markets
#BioIndustry Association #Biologics / Biotechnology #Clarivate #Investment #Market reporting #Mergers and acquisitions #Private investment #Seed funding #UK

UK biotech investment drops after bumper years

Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors.  However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from the UK BioIndustry… Read More

#Business & Investment #News

Drug discovery concept petri dish
#AI / data analytics / healthtech / informatics #Biopharma #Business #Clinical trials #Drug discovery #Genetics / genomics #Genomics #Market reporting

What to expect from drug discovery and development in 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year.   The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal… Read More

#Exclusive Content

#Clarivate #Drug development #Drug discovery #Market reporting #Personalised medicine #Pharmaceuticals

15 drugs likely to be clinical game-changers

A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented.  Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1 billion within five… Read More

#Exclusive Content #Trends & Analysis

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

Non-alcoholic fatty liver disease
#China #Clinical trials #Liver disease #Market reporting #Pharmaceuticals

China’s clinical trial activity in NAFLD increasing

China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM).   As a result, the number of clinical trials conducted in the country for this indication is gradually increasing, driven mostly by international… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

Myeloma
#Cancer research #Clinical trials #Diagnostics #Market reporting #Report

Report: inequalities in access to myeloma clinical trials in Europe 

Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE).   The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack of clinical trials… Read More

#Cancer Research #Market Reports #News

EU flag
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #EFPIA #EU #European Commission #European Federation of Pharmaceutical Industries and Associations #Market reporting

Can Europe become a major player in cell and gene therapy?

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies.  A new report by Charles River Associates… Read More

#Exclusive Content #Market Reports

UK on global map
#BioIndustry Association #Biologics / Biotechnology #Equity finance #Finance #Fundraising #Investment #Life sciences #Market reporting #Private investment #Seed funding #UK

UK remains strongest biotech hub in Europe despite general decline

After a disappointing start to the year, the last few months have seen a boost to fundraising for UK biotech companies. DDW’s Diana Spencer unpacks the Q3 figures and annual predictions from the BioIndustry Association1.  While 2021 was the highest year on record for investments into UK biotech and life… Read More

#Business & Investment #Exclusive Content #Market Reports

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis

Basel map
#Biologics / Biotechnology #Cancer immunotherapy #Immuno-oncology #Market reporting #Oncology #Start-ups

Basel: a centre for ground-breaking oncology 

Listen to this article on the DDW podcast: Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example.  Companies specialising in oncology R&D and therapeutics continue to spring up all… Read More

#Exclusive Content #Market Reports

#Covid-19 #Immunology / Virology & Vaccines #Market reporting

Was England’s vaccine programme value for money?

This most recent report by the Comptroller and Auditor General examines the rollout of the Covid-19 vaccination programme in England up to the end of October 2021, focusing on events up to the end of October 2021 and assessing whether the programme is well placed to meet its objectives… Read More

#Covid-19 #News

#Life sciences #Market reporting #Pharmaceutical research #Public health

How strong is the digital talent in the global pharma sector? 

DDW's Megan Thomas looks at three regions and their approach to digitalisation. 1. United Kingdom  A report published by the Association of the British Pharmaceutical Industry (ABPI) has identified the skills and training conditions needed for the future success of UK life sciences. George Freeman, Minister for Science, Research, and… Read More

#News #Trends & Analysis

#Biopharma #Market reporting #Moderna #Pfizer #Pharma

What drove the top bio/pharma companies’ growth in 2021? 

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported for 14 of… Read More

#News #Trending News #Trends & Analysis